Fig 2.
Population PK model results. (A) Estimated NVP apparent clearance (clearance/bioavailability) versus age for patients not taking RTV or Triomune and with active copies of the CYP2B6 gene (extensive metabolizers). The solid line represents the population-based apparent clearance profile, which was derived using the allometrically scaled median weight for each age group (CDC 50th-percentile weight). (B) Estimated NVP apparent clearance versus age.